Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 12/20 | 1.00 |
| ▸ | CES1 | P23141 | 11/20 | 1.00 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848895 | 0.87 | CES2 (0.81) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL4414671 | 0.86 | CES2 (0.75) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL7260110 | 0.85 | CES2 (0.73) | CES2CES1PARP1 | |
| SCHEMBL15956471 | 0.85 | CES2 (0.73) | CES2CES1HCAR1SLC6A3 | |
| SCHEMBL13246756 | 0.84 | CES2 (0.71) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL4470662 | 0.81 | CES2 (0.68) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL7075313 | 0.79 | CES2 (0.65) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL157714 | 0.79 | HCAR1 (0.73) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL9693658 | 0.79 | CES2 (0.65) | CES2CES1HCAR1CA12CA1 | |
| SCHEMBL4848918 | 0.78 | CES2 (0.73) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | claimed |
| US-8637167-B2 | Light emitting element and light emitting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-8637167-B2 | Light emitting element and light emitting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| EP-1328524-B1 | NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-8227600-B2 | Organometallic complex, and light-emitting element and light-emitting device using the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227600-B2 | Organometallic complex, and light-emitting element and light-emitting device using the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| EP-1749424-B1 | LIGHT EMITTING ELEMENT AND LIGHT EMITTING DEVICE | SEMICONDUCTOR ENERGY LAB (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110196152-A1 | ORGANOMETALLIC COMPLEX, AND LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING DEVICE USING THE SAME | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110196152-A1 | ORGANOMETALLIC COMPLEX, AND LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING DEVICE USING THE SAME | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | disclosed |
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080113216-A1 | Organometallic Complex, And Light-Emitting Element And Light-Emitting Device Using The Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080113216-A1 | Organometallic Complex, And Light-Emitting Element And Light-Emitting Device Using The Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20070241667-A1 | Light Emitting Element and Light Emitting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070241667-A1 | Light Emitting Element and Light Emitting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050054691-A1 | Carboxylesterase inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2005-03-10 | — | — | US | disclosed |
| US-6852728-B2 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-08 | — | — | US | disclosed |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054691-A1 | Carboxylesterase inhibitors | CES1, CES2, BCHE | CES2 2/4885CES1 1/4885HCAR1 2157/4885 |
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | CES1, BCHE, CES2 | CES2 3/4885CES1 1/4885HCAR1 2260/4885 |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | CHRM1, CHRM3, CHRM2 | CES2 337/4885CES1 383/4885HCAR1 413/4885 |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | CHRM1, CHRM3, CHRM2 | CES2 470/4885CES1 568/4885HCAR1 351/4885 |
| US-20110196152-A1 | ORGANOMETALLIC COMPLEX, AND LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING DEVICE USING THE SAME | C5, CRY1, ORC3 | CES2 2482/4885CES1 1770/4885HCAR1 1581/4885 |
| US-20070241667-A1 | Light Emitting Element and Light Emitting Device | LAGE3, MT-ND5, NDUFS5 | CES2 2517/4885CES1 3676/4885HCAR1 4858/4885 |
| US-20080113216-A1 | Organometallic Complex, And Light-Emitting Element And Light-Emitting Device Using The Same | C5, CRY1, ORC3 | CES2 2482/4885CES1 1770/4885HCAR1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.